HomeATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Previous close
$0.22
Year range
$0.11 - $0.89
Avg Volume
27.54K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (CAD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 4.60M | -1.42% |
Net income | -4.21M | 2.39% |
Net profit margin | — | — |
Earnings per share | -0.08 | 0.50% |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 24.91M | -41.20% |
Total assets | 56.36M | -23.56% |
Total liabilities | 30.42M | -0.13% |
Total equity | 25.94M | — |
Shares outstanding | 52.67M | — |
Price to book | 0.44 | — |
Return on assets | -19.71% | — |
Return on capital | -41.30% | — |
Cash Flow
Net change in cash
| (CAD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -4.21M | 2.39% |
Cash from operations | -3.84M | -6.66% |
Cash from investing | 11.04M | 1,975.38% |
Cash from financing | — | — |
Net change in cash | 7.20M | 334.09% |
Free cash flow | -2.47M | -2,419.13% |
About
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Founded
2009
Website
Employees
11
